Laurent Kodjikian, MD, PhD, speaks about the RAINBOW study, evaluating the real-life outcomes of aflibercept in a French population. Results are not far from those of international studies, and significantly better in patients who regularly received the loading dose of 3 monthly injections.
Perspective: Laurent Kodjikian, MD, PhD
Other Perspective
Treat and Extend – Practical guide
Treat and Extend (T&E) has gained wide popularity as a proactive, pragmatic, individualized regi
Biosimilars, a new frontier?
Biosimilars entering the scene of intravitreal injections
Anti-VEGF therapies for AMD: where are we now?
Where are we now with the spread of these therapies for AMD to prevent blindness?
Defining Nonadherence and Nonpersistence to Anti-VEGF Therapies in nAMD
The nAMD Barometer Leadership Coalition published a definition for nonadherence and nonpersistence
Related Articles
